Bank of New York Mellon
VINC

Bank of New York Mellon’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Bank of New York Mellon’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,972
Closed -$238K – 4721
2022
Q1 		$238K Hold
2,972
– – ﹤0.01% 4155
2021
Q4 		$605K Buy
2,972
+443
+18% +$111K ﹤0.01% 3677
2021
Q3 		$818K Buy
2,529
+1,928
+321% +$562K ﹤0.01% 3516
2021
Q2 		$156K Buy
+601
New +$183K ﹤0.01% 4143

Other funds holding VINC

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bank of New York Mellon's VINC Position: Q2 2022 in Review

Bank of New York Mellon sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2022, closing a stake of 2,972 shares — an estimated $238K sold.

Bank of New York Mellon first reported a position in VINC in Q2 2021 and held it in 4 quarters. The position peaked at $818K in Q3 2021. 51 funds tracked by Wall St. Rank hold VINC as of Q2 2022.

  • Bank of New York Mellon reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 2,972 Vincerx Pharma, Inc. Common Stock shares in Q2 2022, an estimated $238K.
  • Bank of New York Mellon first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Bank of New York Mellon's Vincerx Pharma, Inc. Common Stock position peaked at $818K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.